In a day marked by solid gains in the overall market, biotech outperformed broader averages. The Centient Biotech 200™ gained 58.91 points to end at 3456.43, rising 1.73% on the day against .31% for the NYSE Composite and .76% for the Nasdaq. The Centient Biotech 200™ now stands 15% above its August lows.
